Zura Bio Ltd. (ZURA)
1.405
+0.16
(+13.31%)
USD |
NASDAQ |
Nov 10, 16:00
1.39
-0.02
(-1.07%)
After-Hours: 20:00
Zura Bio Enterprise Value : -68.23M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | -68.23M |
| November 06, 2026 | 206.24M |
| November 05, 2026 | 170.61M |
| November 04, 2026 | 199.50M |
| November 03, 2026 | 196.61M |
| November 02, 2026 | 191.80M |
| October 30, 2026 | 201.43M |
| October 29, 2026 | 183.13M |
| October 28, 2026 | 231.28M |
| October 27, 2026 | 223.58M |
| October 26, 2026 | 155.20M |
| October 23, 2026 | 135.94M |
| October 22, 2026 | 152.31M |
| October 21, 2026 | 210.09M |
| October 20, 2026 | 197.57M |
| October 19, 2026 | 179.28M |
| October 16, 2026 | 186.02M |
| October 15, 2026 | 224.54M |
| October 14, 2026 | 237.06M |
| October 13, 2026 | 219.72M |
| October 12, 2026 | 197.57M |
| October 09, 2026 | 197.57M |
| October 08, 2026 | 210.09M |
| October 07, 2026 | 213.95M |
| October 06, 2026 | 193.72M |
| Date | Value |
|---|---|
| October 05, 2026 | 190.83M |
| October 02, 2026 | 208.17M |
| October 01, 2026 | 211.06M |
| September 30, 2026 | 212.98M |
| September 29, 2026 | 176.56M |
| September 28, 2026 | 186.10M |
| September 25, 2026 | 180.37M |
| September 24, 2026 | 191.82M |
| September 23, 2026 | 208.05M |
| September 22, 2026 | 225.22M |
| September 21, 2026 | 224.27M |
| September 18, 2026 | 220.45M |
| September 17, 2026 | 230.95M |
| September 16, 2026 | 234.76M |
| September 15, 2026 | 265.30M |
| September 14, 2026 | 292.02M |
| September 11, 2026 | 292.02M |
| September 10, 2026 | 308.24M |
| September 09, 2026 | 339.73M |
| September 08, 2026 | 379.81M |
| September 04, 2026 | 389.35M |
| September 03, 2026 | 355.95M |
| September 02, 2026 | 335.91M |
| September 01, 2026 | 334.00M |
| August 31, 2026 | 323.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.108M |
| Brainstorm Cell Therapeutics, Inc. | 11.95M |
| Summit Therapeutics, Inc. | 13.66B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 25.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.82M |
| Total Expenses (Quarterly) | 25.82M |
| EPS Diluted (Quarterly) | -0.2022 |
| Earnings Yield | -88.84% |
| Normalized Earnings Yield | -88.84 |